Stockscreener 앱 받기
9.88
9.17%
0.83
시간 외 거래:
9.44
-0.44
-4.45%
전일 마감가:
$9.05
열려 있는:
$9.03
하루 거래량:
604.82K
Relative Volume:
2.50
시가총액:
$290.29M
수익:
$1.78M
순이익/손실:
$-151.77M
주가수익비율:
-1.704
EPS:
-5.7981
순현금흐름:
$-79.40M
1주 성능:
+32.97%
1개월 성능:
+33.88%
6개월 성능:
+32.97%
1년 성능:
+0.92%
1일 변동 폭
$9.0237
$10.59
1주일 범위
$7.195
$10.59
52주 변동 폭
$5.60
$15.57
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
명칭
Cartesian Therapeutics Inc
전화
301-348-8698
주소
7495 NEW HORIZON WAY, FREDERICK
Compare RNAC vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
9.88 | 252.68M | 1.78M | -151.77M | -79.40M | -5.7981 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-09 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-09 | 개시 | Wedbush | Outperform |
| 2024-12-19 | 개시 | BTIG Research | Buy |
| 2024-08-06 | 개시 | TD Cowen | Buy |
| 2024-07-02 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-06-04 | 개시 | Oppenheimer | Outperform |
| 2024-05-24 | 개시 | Mizuho | Buy |
| 2024-04-23 | 재확인 | H.C. Wainwright | Buy |
| 2024-04-23 | 개시 | Leerink Partners | Outperform |
| 2023-08-18 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2022-06-14 | 재확인 | Needham | Buy |
| 2022-06-06 | 개시 | SVB Leerink | Outperform |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-01-26 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-10-01 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-10-01 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-06-12 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-04-28 | 개시 | H.C. Wainwright | Buy |
| 2020-01-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-01-21 | 개시 | William Blair | Outperform |
| 2018-06-27 | 개시 | Janney | Buy |
| 2017-03-30 | 재확인 | UBS | Buy |
모두보기
Cartesian Therapeutics Inc 주식(RNAC)의 최신 뉴스
New partnership gives Cartesian Therapeutics another shot at autoimmune disease market - MSN
RNAC Q1 2026 Earnings: Disappointing EPS Miss Yet Stock Surges 18%Earnings Weakness Phase - newsline.com
Cartesian Therapeutics Announces New Employment Inducement Grant - The Manila Times
New hire at Cartesian gets 6,100 stock options vesting to 2030 - Stock Titan
Cartesian climbs on licensing deal with WestGene for CAR-T therapies - MSN
RNAC: Directors elected and all proposals passed with strong support; no stockholder questions submitted - TradingView
Cartesian Therapeutics, Inc. (RNAC) soars 10.3%: Is further upside left in the stock? - MSN
Cartesian Eyes Multiple 2026-2027 Readouts As Descartes-08 Advances Toward Potential BLA - RTTNews
RNAC Reiterated by Wedbush -- Price Target Maintained at $38.00 - GuruFocus
RNAC Reiterated by BTIG -- Price Target Maintained at $44.00 - GuruFocus
Mizuho Securities Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Announces Target Price $40 - Moomoo
Morgan Stanley Smith Barney (RNAC) lists exercises, vesting and a 3,924-share resale - Stock Titan
RNAC Reiterated by Needham -- Price Target Maintained at $40 - GuruFocus
Cartesian Therapeutics (RNAC) Shares Surge 30% on Licensing Agre - GuruFocus
WestGene Biopharma to collaborate with Cartesian Therapeutics on in vivo CAR-T for autoimmune disease - Traders Union
Why Is Cartesian Therapeutics Stock Trading Higher Today?Cartesian Therapeutics (NASDAQ:RNAC) - Benzinga
Cartesian partners with WestGene for in vivo autoimmune CAR-T - grafa.com
Cartesian inks licensing deal with WestGene (RNAC:NASDAQ) - Seeking Alpha
Cartesian Therapeutics stock jumps on WestGene partnership deal - Investing.com UK
Cartesian Therapeutics stock jumps on WestGene partnership deal By Investing.com - Investing.com Australia
Cartesian Therapeutics Announces In Vivo CAR-T Licensing Alliance - TipRanks
Cartesian strikes licensing agreement with WestGene - The Pharma Letter
Cartesian Therapeutics (RNAC) licenses in vivo CAR-T delivery tech from WestGene - Stock Titan
Cartesian Therapeutics Announces Strategic Licensing Agreement With Westgene Biopharma To Accelerate The Development Of In Vivo Car-T Platform In Autoimmune Diseases - TradingView
Experimental in vivo CAR-T for myasthenia gravis could skip lab manufacturing - Stock Titan
Cartesian Therapeutics (RNAC) Slides 10.8% as Stock Tests Key Support LevelsVol Target Rebalance - newsline.com
Cartesian Therapeutics (RNAC) Faces Sharp Decline, Testing Key Support LevelsADD Alert - newsline.com
[144] Cartesian Therapeutics, Inc. SEC Filing - Stock Titan
Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight - GlobeNewswire Inc.
Cartesian Therapeutics (RNAC) Rises 3.33% as Stock Holds Above Key SupportHedge Fund Exposure - The Legal Advocate
Cartesian Therapeutics (RNAC) Gains 4.6% as Biotech Sector Shows Renewed InterestInstitutional Sentiment - The Legal Advocate
H.C. Wainwright Keeps Their Buy Rating on Cartesian Therapeutics (RNAC) - The Globe and Mail
Cartesian Therapeutics secures up to $150 million financing - The Pharma Letter
Cartesian Therapeutics (RNAC) Secures $150M Credit Facility for Growth Initiatives - GuruFocus
RNAC Maintained by Needham -- Price Target Lowered to $40.00 - GuruFocus
Cartesian Therapeutics stock price target maintained at $40 by Mizuho - Investing.com
Cartesian Therapeutics secures $150M non-dilutive financing, advancing CAR-T trials with key data expected in 2027. - Pluang
Cartesian Therapeutics Secures $150 Million Loan Agreement with K2 HealthVentures and Ankura Trust Company - Minichart
Cartesian Therapeutics Secures Up to $150 Million Credit Facility From K2 HealthVentures - marketscreener.com
Cartesian Therapeutics Lands Up to $150 Million in Non-Dilutive Financing to Support CAR-T Commercialization Push - citybiz
Cartesian Therapeutics IncEnters loan and security agreement on May 22SEC filing - marketscreener.com
Cartesian Secures Major Loan Facility to Extend Runway - TipRanks
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027 - The Manila Times
Milos Miljkovic to Depart Cartesian Therapeutic as Chief Medical Officer; Separation Agreement Expected - TradingView
Cartesian Therapeutics secures up to 150 million dollar credit facility to extend cash runway to 2028 - Traders Union
Cartesian Therapeutics (NASDAQ: RNAC) adds $150M credit line and extends cash runway - Stock Titan
Cartesian Therapeutics Secures up to $150 Million of - GlobeNewswire
Cartesian Therapeutics Inc. (RNAC) Q1 2026 Earnings: Clinical-Stage Biotech Reports Wider-Than-Expected Loss, Stock Ticks HigherDividend Cut Risk - The Legal Advocate
Cartesian Therapeutics (RNAC) Q1 2026 Earnings Miss: Breaking Down the NumbersEarnings Revision Upgrade - Newser
Cartesian Therapeutics Inc (RNAC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):